Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Lonquex Market Expected To Reach $ Billion By 2030 At % CAGR
The historical growth was driven by a rising reliance on chemotherapy regimens, progress in hematology supportive care, the early integration of pegylated growth factors, enhanced cancer survival statistics, and the proliferation of oncology treatment facilities.
The forecast period’s expansion is driven by a higher need for long-acting supportive care medications, greater competition from biosimilars, a growing number of cancer patients, the broadening of outpatient oncology services, and ongoing advancements in hematopoietic growth factors. Key developments shaping the forecast period encompass a growing acceptance of long-acting G-CSF therapies, an intensified focus on chemotherapy-related supportive care, an increasing shift toward single-dose treatment plans, an expansion of biosimilar development initiatives, and a stronger emphasis on lowering infection risks.
Download A Free Sample Report For Comprehensive Market Insights:
Lonquex Market Growth Momentum: Which Factors Are Influencing Demand?
The anticipated increase in cancer incidence is set to drive expansion in the lonquex market in the coming period. Cancer incidence is defined as the count of newly diagnosed cancer cases within a particular population over a specified timeframe, typically measured per 100,000 individuals each year. This rise in cancer incidence stems from influences like an older population, shifts in lifestyle such as higher rates of tobacco and alcohol use, exposure to carcinogens in the environment, inherited genetic factors, and enhanced detection techniques. Lonquex (lipegfilgrastim) reduces the likelihood of infection in cancer patients by boosting white blood cell production, thereby alleviating the effects of neutropenia brought on by chemotherapy. As an example, in February 2024, the World Health Organization, an intergovernmental entity based in Switzerland, projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases recorded in 2022. Consequently, the mounting cancer incidence is fueling growth in the lonquex market.
Lonquex Market Driver: Expansion Of Biosimilars To Drive Growth In The Lonquex Market
The broadening presence of biosimilars is anticipated to accelerate the lonquex market’s growth going ahead. Biosimilars are biologic medicinal products that are notably similar to a previously authorized biologic reference product, showing no clinically significant differences in safety, effectiveness, or strength. This growth in biosimilars is linked to rising pressures to manage healthcare expenses, expiring patents on biologic drugs, a growing burden of chronic conditions, and increasing endorsement of biosimilars by medical professionals and patients. Lonquex (lipegfilgrastim) acts as a biosimilar by mimicking the natural function of granulocyte colony-stimulating factor (G-CSF), stimulating the production and release of neutrophils from bone marrow, thus diminishing infection risks for patients undergoing chemotherapy. For example, in July 2025, Abbott Laboratories, a pharmaceutical firm based in the United States, reported that biosimilars have generated over $64 billion in savings for European healthcare systems so far. Thus, the expansion of biosimilars is propelling the lonquex market forward.
Lonquex Market Segment Analysis Highlighting Growth Areas
The lonquex market covered in this report is segmented –
1) By Indication: Prevention of Chemotherapy-Induced Neutropenia, Treatment of Neutropenia in Hematological Malignancies, Supportive Care for Chemotherapy
2) By Formulation: Injectable Formulation (Solution For Injection), Pre-Filled Syringes Or Auto-Injectors
3) By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Oncology Clinics, Dermatology Clinics, Research Institutions
Lonquex Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the lonquex market are Teva Pharmaceutical Industries Ltd
Access The Complete Lonquex Market Report:
Lonquex Market Geographic Distribution And Regional Opportunities
North America was the largest region in the lonquex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lonquex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model